Therefore, immune checkpoint inhibitors (such as therapies targeting PD1/PD-L1) are significant in treating such tumors as they can alleviate the inhibitory effects on T cells, restoring their ability to target tumor cells. This evidence concerns the gene CD274 and neoplasm.